Management
Anthony Tennyson
CEO and Executive Director
Anthony is the CEO of Graft Polymer (UK) Plc. Anthony also serves as CEO Awakn Life Sciences (CSE: AWKN), a clinical-stage biotechnology company focused on developing therapeutics for substance use and mental health disorders. In addition, Anthony is a non-executive director at Empowerment Plus, an Irish non-profit supporting young people and families at risk.
Before moving into the biotech industry, Anthony accumulated over a decade of experience in financial services. He spent ten years in international strategy and commercial leadership roles at Aon and worked at Merrill Lynch and Bank of Ireland for five years. Anthony holds an MBA and an MSc from University College Dublin (UCD).
Prof David Nutt
Senior Scientific Advisor
Prof. Nutt is Chief Research Officer at Awakn Life Sciences, a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. He is a psychiatrist and the Edmund J. Safra Professor of Neuropsychopharmacology in the Division of Brain Sciences, Dept of Medicine, Imperial College London, where he uses a range of brain imaging techniques to explore the causes of addiction and other psychiatric disorders and to search for new treatments. He completed his medical training at Guy’s Hospital London, trained in neurology to MRCP, before training in psychiatry in Oxford and continuing there as a lecturer and a Wellcome Senior Fellow in Psychiatry. From 1986 to 1986 he was head of the clinical research ward of the National Institute of Alcohol Abuse and Alcoholism in the USA. Returning to the UK in 1988 he set up the Psychopharmacology Unit in Bristol University, an interdisciplinary research group spanning the departments of Psychiatry and Pharmacology before moving to Imperial College London in December 2008, where he leads a similar group with a particular focus on brain imaging and where he heads the Centre for Psychedelic research .
Prof. Nutt is Founding Chair of the charity Drug Science and PAREA the European association for access to research with psychedelics. Previously, he was President f the European Brain Council and of the European College of Neuropsychopharmacology, the British Neuroscience Association and the British As- sociation of Psychopharmacology. In addition, he is a Fellow of the Royal Colleges of Physicians and of Psychiatrists and a Fellow of the Academy of Medical Sciences. He has published over 500 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 36 books.
He broadcasts widely to the general-public both on radio and television. In 2010, The Times Eureka science magazine voted him one of the 100 most important figures in British Science and in 2013 he was awarded the John Maddox Prize from Nature/Sense about Science for standing up for science.
Ryan Neates
Finance Director
Mr Neates holds a Bachelor of Commerce from the University of Western Australia and is a member of Chartered Accountants Australia & New Zealand with 10 years plus experience in finance across public and private sectors. Mr Neates has extensive experience in the public small cap space through his role as Director of Operations at the Corporate Advisory firm, Orana Corporate LLP and also acts as CFO for the AIM listed exploration company, Helix Exploration Plc.
Board
Dennis Purcell
Chairperson
Mr. Purcell is the Founder of Aisling Capital LLC, a major life sciences venture capital firm based in New York City and has previously served as the Fund’s Senior Managing Partner and Advisor. Prior to the formation of Aisling Capital, Mr. Purcell served on the Executive Committee and as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q, formerly Hambrecht and Quist. During his time in the industry, he has invested in, raised capital for, and advised hundreds of life sciences companies.
Mr. Purcell currently serves on the board of directors of Real Endpoints, Ichnos Pharmaceuticals, Summus Global, Shorla Oncology, and Embera Pharma. He is also an advisor to Better Health, Cellevolve and xCellerate. He has previously served on the Boards of public and private Life Sciences companies.
In addition, Mr. Purcell serves as an Executive-in-Residence at Columbia University and as an Endowment Committee member at the University of Delaware, where he also serves on the Pharmaceutical Innovation Board.
Nicholas Nelson
Non-Executive Director
Nicholas entered the City in 1985 as an apprentice market-maker and moved from there into stockbroking in 1986. What followed was 13 year career in investment management and small-cap company research.
In 1998, he moved into the Financial PR industry for a further 13 years advising listed companies including oversight of 100 plus IPOs. His objective: to develop recognition for his clients as great investment opportunities.
Overlapping the above, from 2002, Nicholas has taken his talents in-house by joining the boards of, so far, 8 AIM and AQSE companies as they moved from private to public life.
Anthony Tennyson
CEO and Executive Director
Anthony is the CEO of Graft Polymer (UK) Plc. Anthony also serves as CEO Awakn Life Sciences (CSE: AWKN), a clinical-stage biotechnology company focused on developing therapeutics for substance use and mental health disorders. In addition, Anthony is a non-executive director at Empowerment Plus, an Irish non-profit supporting young people and families at risk.
Before moving into the biotech industry, Anthony accumulated over a decade of experience in financial services. He spent ten years in international strategy and commercial leadership roles at Aon and worked at Merrill Lynch and Bank of Ireland for five years. Anthony holds an MBA and an MSc from University College Dublin (UCD).